

****New release June 2009****

MarketVIEW: Chikungunya virus (CAT: VADIP005)

Proposal No/#PO	:	[Enter client specific #PO]
Product Name	:	Comprehensive commercial evaluation of Chikungunya virus vaccine
Project Initiation Date	:	n/a
Billable days	:	n/a
Initiator(s)	:	[Enter client name, function and address]
Therapeutic Area	:	<i>Emerging viruses</i>
Product (if applicable)	:	CAT No: VAMV005, published June 2009

Background

Chikungunya virus (CHIK) is an arthropod-borne RNA virus (arbovirus) which causes an acute illness including fever, skin rash, and incapacitating arthralgia¹. In some cases the virus can cause recurrent disease, neurological complications and severe neonatal disease (encephalopathy). Although CHIK is endemic in Africa/Southeast Asia, recent outbreaks during 2004–2007 have reached new geographical areas where cases are now reported in Europe, Hong-Kong, Canada, Taiwan and the USA. In some cases, these are directly associated with the return of infected tourists from India and islands of the Indian Ocean. Moreover, in 2007, the first CHIK outbreak was recorded in a temperate region of North Eastern of Italy with more than 200 cases². Because there is no specific treatment for CHIK infection many institutions have considered the prospect for a prophylactic vaccine

This expert report comprises of two deliverables 1) A commercial summary presentation and 2) An Excel-based commercial forecast model which details potential demand (doses) and gross sales revenues (\$USD) in potential target markets for a prophylactic Chikungunya vaccine. For each target market characteristics and model assumptions are clearly presented along with relevant cases studies of other vaccines currently licensed for travelling populations and private markets of SE Asia. The report has been structured to provide expert guidance as to the commercial viability of a CHIK vaccine.

¹ Robinson MC. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952–53. I. Clinical features. *Trans R Soc Trop Med Hyg.* 1955;49(1):28–32

² Watson R. Europe witnesses first local transmission of chikungunya fever in Italy. *BMJ* 2007;335(7619):532-3

PRODUCT CONTENTS:

Published June 2009 (CAT No: VAMV005)

NOTE: This product comprises of 2 deliverables. An Executive presentation (MS Powerpoint) and accompanying forecast model (MS Excel)

Executive Presentation (contents)

Author's Note
Executive summary
Comparing mosquito borne diseases
Countries where people have been infected with CHIK
CHIK vaccine: comments on ideal product profile
Defining target groups for a CHIK vaccine
CHIK vaccine: endemic markets (private)
Broad assumptions for endemic market uptake
Commercial model assumptions: endemic markets (private)
Estimating public funding for a CHIK vaccine: GAVI
CHIK vaccine: Western travellers
Broad assumptions for traveller's market
Commercial model assumptions: Western travellers
CHIK vaccine: military use (Western)
Vaccines typically administered to US military personnel
Broad assumptions for military use (Western)
Comments on potential military markets (Western)
Commercial assumptions: military use
CHIK vaccine: Western stockpile for local use
United States: risk of CHIK transmission
Broad assumptions for CHIK vaccine stockpiling/vaccination
Commercial assumptions: Western stockpiles
CHIK vaccine: total available volume/revenues (\$USD)/year
CHIK vaccine: forecast available volume – endemic (private)
CHIK vaccine: forecast available volume – travellers (Western)
Future competitive environment
Key potential upsides
Key challenges and risks
Appendices
Bibliography
About VacZine Analytics
Disclaimer

PAGES: ~35 MS Powerpoint slides, fully referenced/sourced. Available in .pdf form

Forecast Model (worksheets)

Title sheet
Author's Note
Volume/value summary (All)
Charts – volume/value
Traveller markets →
US – travellers
EU – travellers
Japan – travellers
Endemic markets (private) →
Endemic – private (Africa)
Endemic – private (SE Asia)
Endemic – private (India)
Source material
Traveller database (All)
Traveller database (US)
Traveller database (Japan)
Traveller database (EU)
Urban populations – (Africa)
Urban populations – (SE Asia)
Urban populations – (India)
Temperate zones – US
CHIK countries – GAVI funding to date
Back page

PROJECT METHODOLOGY:

VacZine Analytics has conducted a comprehensive secondary research to review all available information regarding Chikungunya in major EU/Canada and US markets. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Commercial evaluation for the potential of Chikungunya vaccine is based upon expert “in house” knowledge of target markets along with pricing/penetration estimations in each chosen region.

PRODUCT PRICE:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:


- USD \$7995.00/ GBP £4995.00 (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 15% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY:

1. World Health Organisation (WHO) website. Available at: www.who.int. Accessed June 2009
2. US Centers for Disease Control and Prevention (CDC). Available at: http://www.cdc.gov/ncidod/dvbid/Chikungunya/CH_GlobalMap.html. Accessed: May 2009
3. Edelman R., et al. Phase II safety and immunogenicity study of live Chikungunya virus vaccine (TSI-GSD-218). *Am J Trop Med Hyg.* 62(6), 2000 pp 681-685
4. Muthumani K., et al. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. *Vaccine* 2008. 6(40) 5128-5134
5. Levine O. The pneumococcal vaccine investment case. PneumoADIP GAVI Alliance Presentation. Available at: www.gavialliance.org/resources/19brd_IC_Pneumo_Levine.ppt. Accessed June 2009
6. Parashar UD., et al. Rotavirus and severe childhood diarrhea. *Emerg Infect Dis.* Vol. 12, No. 2, February 2006. Available at: <http://www.cdc.gov/ncidod/EID/vol12no02/05-0006.htm>. Accessed June 2009
7. Human Papilloma Virus Vaccines. A new tool for cancer prevention. Pan American Health Organisation Factsheet. Available at: <http://amro.who.int/English/AD/FCH/IM/HPV-FactSheet1.pdf>. Accessed June 2009
8. World Health Organisation (WHO) website. Regional offices for SE Asia and Western Pacific. Available at: www.who.int. Accessed June 2009
9. GAVI Alliance Website. Available at: <http://www.gavialliance.org/index.php>. Accessed June 2009
10. Independent Review Committee Report on the yellow fever stockpile investment case. Delhi GAVI Board Meetings 6-7 December 2005. Available at: http://www.gavialliance.org/resources/17brd_7_YellowFever_ICreview_6Dec2005.pdf. Accessed June 2009
11. Grabenstein JD., et al. Immunization to Protect the US Armed Forces: Heritage, Current Practice. Prospects. Available at: <http://www.dtic.mil/cgi-bin/GetTRDoc?AD=ADA495556&Location=U2&doc=GetTRDoc.pdf>. Accessed June 2009
12. Department of Defence. Active Duty Military Personnel Strengths by Regional Area and By Country. Available at: <http://siadapp.dmdc.osd.mil/personnel/MILITARY/history/hst0812.pdf>. Accessed June 2009.
13. UK Defence Statistics. Available at: <http://www.dasa.mod.uk/modintranet/UKDS2008/c2/table207.html>. Accessed June 2009
14. Worldwide military deployments. Available at: <http://www.globalsecurity.org/military/world/deploy.htm>. Accessed June 2009
15. US Military. Armed Forces Epidemiological Board (AEFB) Meeting 21 September 2004. Available at: <http://www.health.mil/dhb/meeting-afeb-2004-09.cfm>. Accessed June 2009
16. Chikungunya Fever Diagnosed Among International Travellers – US 2005-2006. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5538a2.htm>. Accessed May 2009.
17. Monath, TP. Chikungunya – could it be the next West Nile? *One Health Newsletter*. University of Florida. Volume 1 Issue 2
18. US Centers For Disease Control and Prevention (CDC). National Center for Preparedness, Detection, and Control of Infectious Diseases. Available at: <http://www.cdc.gov/ncidod/srp/drugs/formulary.html>. Accessed June 2009
19. Botulism Factsheet. Center for Biosecurity. Uni of Pittsburgh Medical Center. Available at: http://www.upmc-biosecurity.org/website/focus/agents_diseases/fact_sheets/botulinum.html. Accessed June 2009
20. For whole nation outlined in **DiseaseINFOPACK**. Chikungunya virus (CAT No: VADIP013), published by **VacZine Analytics** May 2009
21. Rosenthal SR., et al. Developing New Smallpox Vaccines. *Emerg Inf Dis* (2001). Vol 7 No 6
22. Webb GF. Being Prepared: Modelling the Response to an Anthrax Attack. *Ann Intern Med* 2005; 142: 667-668
23. US Strategic National Stockpile. Available at: <http://www.remm.nlm.gov/sns.htm>. Accessed June 2009
24. **Adapted from:** GAVI's Investment Strategy, GAVI Alliance and Fund Board Meeting – 25-26 June 2008. Available at: http://www.gavialliance.org/resources/3_Vaccine_Investment_Strategy.pdf. Accessed June 2009

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on-line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. **Force Majeure:** The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, influenza pandemic, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request or at www.vacZine-analytics.com

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is a new strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009



VacZine Analytics[®]
Bringing life to vaccine strategy...

Bringing life to vaccine strategy...

www.vacZine-analytics.com

Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44 (0) 1279 654514 **e-mail:** info@vacZine-analytics.com

